Abstract
Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Despite therapy with surgery, radiation and chemotherapy, the prognosis remains poor, and the demand for more effective treatments is high. Research has increased our understanding of the molecular pathways important for gliomagenesis and disease progression, including the epidermal growth factor receptor (EGFR) and downstream phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway. Targeted therapeutics have been developed against these receptors and pathways. This article will review the rationale and current evidence for inhibitors of this signaling axis.
Keywords: Glioblastoma, EGFR inhibitors, mTOR inhibitors, treatments, review, chemotherapy, disease, Epidermal growth, phosphatidylinositol, mammalian target, rapamycin, high frequency, phenotype, tyrosine, chromosome, glycoprotein, cell, protein kinase C, tumor proliferation, exons, ligand binding, immunohistochemistry, antibodies, vaccines, glioma, oral, tissue, phosphorylation, hepatic enzyme system, cetuximab, solubility, blood concentration ratios, liver, hybridization, dose, enzyme, anti-epileptic, vaccine, mutations, tumor, temsirolimus, cholesterolemia, lymphopenia, tyrosine kinase receptor
Current Cancer Therapy Reviews
Title: Targeting the Epidermal Growth Factor Pathway as Therapy for Glioblastoma
Volume: 7 Issue: 1
Author(s): Eudocia C. Quant, Catherine L. Nutt, Daphne Wang and Tracy T. Batchelor
Affiliation:
Keywords: Glioblastoma, EGFR inhibitors, mTOR inhibitors, treatments, review, chemotherapy, disease, Epidermal growth, phosphatidylinositol, mammalian target, rapamycin, high frequency, phenotype, tyrosine, chromosome, glycoprotein, cell, protein kinase C, tumor proliferation, exons, ligand binding, immunohistochemistry, antibodies, vaccines, glioma, oral, tissue, phosphorylation, hepatic enzyme system, cetuximab, solubility, blood concentration ratios, liver, hybridization, dose, enzyme, anti-epileptic, vaccine, mutations, tumor, temsirolimus, cholesterolemia, lymphopenia, tyrosine kinase receptor
Abstract: Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Despite therapy with surgery, radiation and chemotherapy, the prognosis remains poor, and the demand for more effective treatments is high. Research has increased our understanding of the molecular pathways important for gliomagenesis and disease progression, including the epidermal growth factor receptor (EGFR) and downstream phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway. Targeted therapeutics have been developed against these receptors and pathways. This article will review the rationale and current evidence for inhibitors of this signaling axis.
Export Options
About this article
Cite this article as:
C. Quant Eudocia, L. Nutt Catherine, Wang Daphne and T. Batchelor Tracy, Targeting the Epidermal Growth Factor Pathway as Therapy for Glioblastoma, Current Cancer Therapy Reviews 2011; 7 (1) . https://dx.doi.org/10.2174/157339411794474146
DOI https://dx.doi.org/10.2174/157339411794474146 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Infrared Spectroscopy and Imaging in Cancer Diagnosis
Current Medicinal Chemistry Nerve Growth Factor Receptors and Signaling in Breast Cancer
Current Cancer Drug Targets Therapeutic Perspectives of Inhibitors of Endocannabinoid Degradation
Current Drug Targets - CNS & Neurological Disorders The Chemical Defensive System in the Pathobiology of Idiopathic Environment- Associated Diseases
Current Drug Metabolism Cancer Nanotechnology - Prospects for Cancer Diagnostics and Therapy
Current Cancer Therapy Reviews Eliminating Ovarian Cancer Stem Cells: A Potential Therapeutic Target for Ovarian Cancer Chemoresistance
Current Protein & Peptide Science Imidazoles and Benzimidazoles as Tubulin-Modulators for Anti-Cancer Therapy
Current Medicinal Chemistry The PI3K Pathway at the Crossroads of Cancer and the Immune System: Strategies for Next Generation Immunotherapy Combinations
Current Cancer Drug Targets Natural Endoperoxides as Drug Lead Compounds
Current Medicinal Chemistry Association of Posture Instability with Dopamine Drop of Nigrostriatal System and Hypometabolism of Cerebral Cortex in Parkinson’s Disease
Current Neurovascular Research A Novel Gene Selection Method Based on Sparse Representation and Max-Relevance and Min-Redundancy
Combinatorial Chemistry & High Throughput Screening Highlights in Peptide Nanoparticle Carriers Intended to Oral Diseases
Current Topics in Medicinal Chemistry Novel Agents Aiming at Specific Molecular Targets Increase Chemosensitivity and Overcome Chemoresistance in Hematopoietic Malignancies
Current Pharmaceutical Design Ionotropic Glutamate Receptors & CNS Disorders
CNS & Neurological Disorders - Drug Targets Somatostatin, Somatostatin Analogs and Somatostatin Receptor Dynamics in the Biology of Cancer Progression
Current Molecular Medicine Cancer Drug Discovery Targeting Histone Methyltransferases: An Update
Current Medicinal Chemistry Targeted Therapy Towards Cancer-A Perspective
Anti-Cancer Agents in Medicinal Chemistry Nanomedicine and its Application in Treatment of Microglia-mediated Neuroinflammation
Current Medicinal Chemistry Recent Patents on Mesenchymal Stem Cell Mediated Therapy in Inflammatory Diseases
Recent Patents on Inflammation & Allergy Drug Discovery TGFß, a Potent Regulator of Tumor Microenvironment and Host Immune Response, Implication for Therapy
Current Molecular Medicine